By Josh Beckerman
Shares of Journey Medical were up 21%, to $2.03, as it reported favorable topline Phase 1 study data for a papulopustular rosacea treatment it is developing in collaboration with Dr. Reddy’s Laboratories.
Journey Medical said it is “very pleased” with the results for DFD-29, which indicate that it can be safely used for up…
Read the full article here
